| Name | Title | Contact Details |
|---|
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
Scout.com Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.